Watching Incyte; Traders Circulate Research Report From Unemon Suggesting Novartis Emerges As The Ideal Acquirer, Says "Would Not Be Surprised To See A $105-$110 Deal In The Coming Weeks"
Incyte Corporation +1.73%
Novartis AG Sponsored ADR -0.68%
Incyte Corporation INCY | 95.93 | +1.73% |
Novartis AG Sponsored ADR NVS | 154.03 | -0.68% |
https://unemon.com/ResearchEasy/202411_INCY/20241115_INCY_Takeover_POA.html
